Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ESMO 2022: Highlights, commentary and analysis

Dr Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

OncoAlert and ecancer weekly round up for August 15th - 21st, 2022

Dr Gil Morgan - Skåne University Hospital in Lund, Sweden

OncoAlert and ecancer weekly round up for August 15th - 21st, 2022 ( Dr Gil Morgan - Skåne University Hospital in Lund, Sweden )

Working to improve global cancer care access in low middle-income countries

Dr Julie Gralow, Prof Eduardo Cazap

Working to improve global cancer care access in low middle-income countries ( Dr Julie Gralow, Prof Eduardo Cazap )

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDM...

Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA

EHA update: Lenalidomide, bortezomib, and dexamethasone ASCT to progress for NDMM ( Dr Paul Richardson - Dana Farber Cancer Institute, Boston, USA )

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show...

Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany

Isatuximab, lenalidomide, bortezomib and dexamethasone as induction therapy show a superior MRD negativity rate for newly diagnosed MM patients ( Dr Elias Mai - University Hospital Heidelberg, Heidelberg, Germany )

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity i...

Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA

COSMIC-021: Cabozantinib plus atezolizumab gives encouraging clinical activity in inoperable locally advanced/metastatic urothelial carcinoma ( Dr Sumanta K. Pal - City of Hope Comprehensive Cancer Center, Duarte, USA )

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03 ( Dr Erika Hamilton - Sarah Cannon Research Institute, Tennessee, USA )

High-dose ifosfamide standard of care for recurrent and primary refractory ewing...

Dr Martin McCabe - University of Manchester, Manchester, England

$High-dose ifosfamide standard of care for recurrent and primary refractory ewing sarcoma ( Dr Martin McCabe - University of Manchester, Manchester, England )$

Lung cancer in India

Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India

Lung cancer in India ( Dr Krishnamani Kalpathi - American Oncology Institute, Hyderabad, India )

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO

Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Fr...

OncoAlert Colloquium Day 6: Gynaecological oncology, IGCS and ESO ( Dr Don Dizon, Dr Allison Betof Warner, Dr Giancarlo Pruneri, Dr Pierfrancesco Franco & Dr Kathleen Schemeler )

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more

Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla...

OncoAlert Colloquium Day 5: SWOG, OncoAlliance and more ( Dr John Haanen, Dr Vivek Subbiah, Dr Christian Rolfo, Dr Jessica Hwang, Dr Nagla Karim, Dr Fumiko Chino, Dr Narjust Duma & Dr Nicole Kuderer )

OncoAlert Colloquium Day 4: GI oncology and EONS

Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewi...

OncoAlert Colloquium Day 4: GI oncology and EONS ( Dr Cathy Eng, Dr Yelena Janjigian, Ms Stacy Hurt, Ms Allison Rosen, Dr Mark Lewis, Dr Nina Niu Sanford, Mr Johan de Munter & Dr Merel Van Klinken )

More from ecancer